Risk Functions and the Primary Prevention of Cardiovascular Disease;Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares

Revista Espanola de Cardiologia

Volumn 61, Issue 4, 2008, Pages 404-416

  Grau, María ^a   Marrugat, Jaume ^a,b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Cardiovascular disease; Cardiovascular risk; Cardiovascular risk functions; Coronary disease; Primary prevention; Risk factor; Risk of coronary disease

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; PATIENT SELECTION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SPAIN;

EID: 45249120823     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13117732     Document Type: Article

References (123)

1. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-7.
2. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-8.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52.
4. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32-8.
5. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-414.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III). JAMA. 2001;285:2486-97.
7. Miguel García F, Montero Alonso MJ, García Ortiz A. Tablas de riesgo cardiovascular y evidencias. En defensa de la tabla de Framingham calibrada. Aten Primaria. 2004;33:409-11.
8. Maiques Galán A. Valoración del riesgo cardiovascular. ¿Qué tabla utilizar? Aten Primaria. 2003;32:586-9.
9. Maiques Galán A, Villar Alvarez F, Llor Vila C, Torcal Laguna J. El riesgo coronario en España y el tratamiento con fármacos hipolipemiantes. Aten Primaria. 2003;32:420-2.
10. Lobos Bejarano JM, Brotons Cuixart C. Nuevas estrategias en la prevención cardiovascular: la importancia del consenso. Aten Primaria. 2004;34:389-91.
11. Solanas Saura P, Ramos Blanes R, Cordón Granados F; investigadores del Estudio REGICOR. Nadie es profeta en su tierra. Aten Primaria. 2004;34:107.
12. Baena Díez JM, Salas Gaetgens LH, Altes Vaques E, Sánchez Pérez R. REGICOR mejor que Framingham en el cálculo del riesgo coronario: una buena noticia para nuestros pacientes. Med Clin (Barc). 2004;122:597-8.
13. Gil-Guillén V, Orozco-Beltrán D, Maiques-Galán A, Aznar-Vicente J, Navarro J, Cea-Calvo L, et al. Concordancia de las escalas REGICOR y SCORE para la identificación del riesgo cardiovascular alto en la población española. Rev Esp Cardiol. 2007;60:1042-50.
14. Buitrago F, Cañón-Barroso L, Díaz-Herrera N, Cruces-Muro E, Escobar-Fernández M, Serrano-Arias JM. Comparación de las tablas REGICOR y SCORE para la clasificación del riesgo cardiovascular y la identificación de pacientes candidatos a tratamiento hipolipemiante o antihipertensivo. Rev Esp Cardiol. 2007;60:139-47.
15. Buitrago Ramírez F, Cañón Barroso L, Díaz Herrera N, Cruces Muro E, Bravo Simón B, Pérez Sánchez I. Comparación entre la tabla del SCORE y la función Framingham-REGICOR en la estimación del riesgo cardiovascular en una población urbana seguida durante 10 años. Med Clin (Barc). 2006;127:368-73.
16. Ramos R, Solanas P, Subirana I, Vila J. Comparación entre la tabla del SCORE y la función de Framingham-REGICOR en la estimación del riesgo cardiovascular. Med Clin (Barc). 2007;128:477-8.
17. Baena Díez JM, Del Val Garcia JL, Héctor Salas Gaetgens L, Sánchez Pérez R, Altes Vaques E, Deixens Martínez B, et al. Comparación de los modelos SCORE y REGICOR para el cálculo del riesgo cardiovascular en sujetos sin enfermedad cardiovascular atendidos en un centro de salud de Barcelona. Rev Esp Salud Publica. 2005;79:453-64.
18. Anderson KM, Odell PM, Wilson P, Kannel WF. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-8.
19. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. CHD Risk Prediction Group. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. JAMA. 2001;286:180-7.
20. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
21. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany: results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24:937-45.
22. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24:1903-11.
23. Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002;31:817-22.
24. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84:238-44.
25. Liu J, Hong Y, D'Agostino RB, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291:2591-9.
26. Ramos R, Solanas P, Cordón F, Rohlfs I, Elosua R, Sala J, et al. Comparación de la función de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc). 2003;121:521-6.
27. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
28. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health. 2003;57:634-8.
29. Marrugat J, Subirana I, Comín E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61:40-7.
30. Cristóbal J, Lago F, De la Fuente J, González-Juanatey JR, Vázquez-Belles P, Vila M. Ecuación de Framingham de Wilson y ecuación de REGICOR. Estudio comparativo. Rev Esp Cardiol. 2005;58:910-5.
31. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
32. Sans S, Fitzgerald AP, Royo D, Conroy R, Graham I. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60:476-85.
33. Verschuren WMM, Jacobs DR, Bloemberg BPM, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274:131-6.
34. Van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1-8.
35. Ramos R, Marrugat J. Valoración del riesgo cardiovascular en la población. En: Alfonso del Río Ligorit, editor. Manual de cardiología preventiva. Madrid: SMC; 2005. p. 43-55.
36. Kannel WB, D'Agostino RB, Sullivan L, Wilson PW. Concept and usefulness of cardiovascular risk profiles. Am Heart J. 2004;148:16-26.
37. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation. 1998;97:1876-87.
38. Medrano MJ, Pastor-Barriuso R, Boix R, Del Barrio JL, Damián J, Álvarez R, et al, investigadores del estudio ZACARIS. Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española. Rev Esp Cardiol. 2007;60:1250-6.
39. Banegas JR, Rodriguez-Artalejo F, Dominguez-Rojas V, Del Rey Calero J. How much benefit could be obtained from cardiovascular disease intervention programs? Rev Epidemiol Sante Publique. 1992;40:313-22.
40. Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Comm Health. 1998;52:707-15.
41. Ferrieres J. The French paradox: lessons for other countries. Heart. 2004;90:107-11.
42. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3:144-53.
43. Tomás M, Latorre G, Senti M, Marrugat J. Función antioxidante de las lipoproteínas de alta densidad: un nuevo paradigma en la arteriosclerosis. Rev Esp Cardiol. 2004;57:557-69.
44. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006;97:372-5.
45. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776-85.
46. Protocolo del Estudio VERIFICA (Validez de la Ecuación de Riesgo Individual de Framingham de Incidentes Coronarios Adaptada) [manual en internet]. Barcelona: 2002 [citado 30 Ago 2007]. Disponible en: http://www.regicor.org/fitxers_generals/ProtocoloVERIFICA.pdf
47. Gil M, Martí H, Elosua R, Grau M, Sala J, Masiá R, et al. Análisis de la tendencia en la letalidad, incidencia y mortalidad por infarto de miocardio en Girona entre 1990 y 1999. Rev Esp Cardiol. 2007;60:349-56.
48. Lindman AS, Selmer R, Tverdal A, Pedersen JI, Eggen AE, Veierod MB. The SCORE risk model applied to recent population surveys in Norway compared to observed mortality in the general population. Eur J Cardiovasc Prev Rehabil. 2006;13:731-7.
49. Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil. 2005;12:442-50.
50. Ulmer H, Kollerits B, Kelleher C, Diem G, Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women. Eur J Cardiovasc Prev Rehabil. 2005;12:433-41.
51. Lindman AS, Veierød MB, Pedersen JI, Tverdal A, Njølstad I, Selmer R. The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway. Eur J Cardiovasc Prev Rehabil. 2007;14:501-7.
52. Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005;27:93-100.
53. Marrugat J, Sala J. Nuevos instrumentos y los riesgos de siempre. Rev Esp Cardiol. 2007;60:464-7.
54. Comín E, Solanas P, Cabezas C, Subirana I, Ramos R, Gené-Badía J, et al. Rendimiento de la estimación del riesgo cardiovascular en España utilizando distintas funciones. Rev Esp Cardiol. 2007;60:693-702.
55. Jones AF, Walker J, Jewkes C, Game FL, Bartlett WA, Marshall T, et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart. 2001;85:37-43.
56. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347-60.
57. Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y de las tendencias entre 1997 y 2005. Rev Esp Cardiol. 2002;55:337-46.
58. WHO Statistical Information System (WHOSIS). World Health Organization (WHO) [citado 1 Ene 2008]. Disponible en: http://www.who.int/whosis/
59. Beaglehole R. International trends in coronary heart disease mortality and incidence rates. J Cardiovasc Risk. 1999;6:63-8.
60. Estudio de mortalidad en España. Instituto de Salud Carlos III [citado 4 Ene 2008]. Disponible en: http://193.146.50.130/raziel.php
61. Marrugat J, Elosua R, Aldasoro E, Tormo MJ, Vanaclocha H, Segura A, et al. Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998. Eur J Epidemiol. 2004;19:831-9.
62. Marrugat J, Arboix A, García-Eroles L, Salas T, Vila J, Castell C, et al. Estimación de la incidencia poblacional y la mortalidad de la enfermedad cerebrovascular establecida isquémica y hemorrágica en 2002. Rev Esp Cardiol. 2007;60:573-80.
63. Protocolo del Estudio HERMES (Harmonización de las ecuaciones de riesgo en el mediterráneo sur de Europa) [manual en internet]. Barcelona: 2002 [citado 30 Ago 2007]. Disponible en: http://www.regicor.org/ fitxers_generals/ProtocoloHERMES.pdf
64. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:1301-7.
65. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/ TexCAPS. JAMA. 1998;279:1615-22.
66. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-30.
67. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA. 2002;288:1388-95.
68. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307-13.
69. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59.
70. The Stroke Council. Statins after ischemic stroke and transient ischemic attack. Stroke. 2004;35:1023.
71. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
72. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2003;57:640-651.
73. Maiques Galán A, Antón García F, Franch Taix M, Albert Ros X, Aleixandre Martí E, Collado Gil A. Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las Sociedades Europeas. Med Clin (Barc). 2004;123:681-5.
74. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronay and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
75. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
76. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63.
77. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-96.
78. Jackson R, Lynch J, Harper S. Preventing coronary heart disease. BMJ. 2006;332:617-8.
79. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326-36.
80. Grau M, Subirana I, Elosua R, Solanas P, Ramos R, Masiá R, et al. Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain. Eur J Cardiovasc Prev Rehabil. 2007;14:653-9.
81. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003,21:1011-53.
82. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.
83. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 1997;20:935-42.
84. Panzram G. Mortality and survival in type 2 (on-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:123-31.
85. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men and women: the Framingham study. JAMA. 1988;260:3456-60.
86. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
87. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901-7.
88. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324:1-5.
89. Lee CD, Folsom AR, Pankow JS, Brancati FL; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855-60.
90. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717-23.
91. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161:242-7.
92. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002;40:954-60.
93. Masiá R, Sala J, Rohlfs I, Piulats R, Manresa JM, Marrugat J. Prevalencia de diabetes mellitus en la provincia de Girona, España: el estudio REGICOR. Rev Esp Cardiol. 2004;57:261-4.
94. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360-9.
95. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47 Suppl:C19-31.
96. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol. 2004;4:124-31.
97. Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med. 2006;145:35-42.
98. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368-73.
99. Morrison AC, Bare LA, Chambless LE, Ellis SG, Malloy M, Kane JP, et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2007;166:28-35.
100. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291:2204-11.
101. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210-5.
102. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158-65.
103. Simon A, Chironi G, Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J. 2007;28:2967-71.
104. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483-94.
105. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22.
106. Bots ML, Baldassarre D, Simon A, De Groot E, O'Leary DH, Riley W, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007;28:398-406.
107. Fowkes FG, Low LP, Tuta S, Kozak J; AGATHA Investigators. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27:1861-7.
108. Eldrup N, Sillesen H, Prescott E, Nordestgaard BG. Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J. 2006;27:316-22.
109. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538-45.
110. Braunwald E. Epilogue: What do clinicians expect from imagers? J Am Coll Cardiol. 2006;47 Suppl C:C101-3.
111. Taylor AJ, Merz CN, Udelson JE. 34th Bethesda Conference: Executive summary - can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? J Am Coll Cardiol. 2003;41:1860-2.
112. Lutgens E, Van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, et al. Atherosclerotic plaque rupture: local or systemic process? Arterioscler Thromb Vasc Biol. 2003;23:2123-30.
113. Heistad DD. Unstable coronary-artery plaques. N Engl J Med. 2003;349:2285-7.
114. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-72.
115. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-8.
116. Naghavi M, Falk E, Hecht HS, Jamieson MJ, Kaul S, Berman D, et al; SHAPE Task Force. From vulnerable plaque to vulnerable patient - Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol. 2006;98:H2-15.
117. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-65.
118. Van der Meer IM, De Maat MP, Kiliaan AJ, Van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163:1323-8.
119. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109:1349-53.
120. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
121. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-5.
122. Wilson PW, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165:2473-8.
123. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737-45.